| Literature DB >> 28435525 |
Alexander Döbber1,2, Athena F Phoa1, Ramzi H Abbassi1, Brett W Stringer3, Bryan W Day3, Terrance G Johns4,5, Mohammed Abadleh2, Christian Peifer2, Lenka Munoz1.
Abstract
Photoremovable protecting groups added to bioactive molecules provide spatial and temporal control of the biological effects. We present synthesis and characterization of the first photoactivatable small-molecule tubulin inhibitor. By blocking the pharmacophoric OH group on compound 1 with photoremovable 4,5-dimethoxy-2-nitrobenzyl moiety we developed the photocaged prodrug 2 that had no effect in biological assays. Short UV light exposure of the derivative 2 or UV-irradiation of cells treated with 2 resulted in fast and potent inhibition of tubulin polymerization, attenuation of cell viability, and apoptotic cell death, implicating release of the parent active compound. This study validates for the first time the photoactivatable prodrug concept in the field of small molecule tubulin inhibitors. The caged derivative 2 represents a novel tool in antitubulin approaches.Entities:
Keywords: Photoactivatable caged prodrug; glioblastoma; tubulin inhibitor
Year: 2017 PMID: 28435525 PMCID: PMC5392771 DOI: 10.1021/acsmedchemlett.6b00483
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345